IONS
NASDAQ
US
Ionis Pharmaceuticals, Inc. - Common Stock
$74.79
▼ $-0.34
(-0.45%)
Vol 1.8M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$12.8B
ROE
-44.3%
Margin
-26.5%
D/E
198.53
Beta
0.27
52W
$24–$84
Wall Street Consensus
29 analysts · Apr 20269
Strong Buy
13
Buy
7
Hold
0
Sell
0
Strong Sell
75.9%
Buy Rating
Price Chart
Similar Stocks
INCY
Incyte Corp
P/E 16.3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33.0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
EXEL
Exelixis Inc
P/E 17.3
$11.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21.9
$11.4B
PRAX
Praxis Precision Medicines Inc
$7.4B
ARWR
Arrowhead Pharmaceuticals Inc
$9.0B
PCVX
Vaxcyte Inc
$6.0B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.35 | $-1.41 | $-0.06 |
| Sep 2025 | $-1.26 | $-0.80 | +$0.46 |
| Jun 2025 | $-0.44 | $0.70 | +$1.14 |
| Mar 2025 | $-1.14 | $-0.93 | +$0.21 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -45.5% | -45.5% | -45.5% | -45.5% | -44.3% | -44.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 27.3% | -28.4% | -28.4% | -28.4% | -26.5% | -26.5% |
| Gross Margin | 99.1% | 98.8% | 98.8% | 98.8% | 98.7% | 98.7% |
| D/E Ratio | 198.76 | 198.76 | 198.76 | 198.76 | 198.53 | 198.53 |
| Current Ratio | 2.87 | 2.87 | 2.87 | 2.87 | 2.79 | 2.79 |
Key Ratios
ROA (TTM)
-8.7%
P/S (TTM)
13.24
P/B
9.4
EPS (TTM)
$-1.71
CF/Share
$-2.77
Rev Growth 3Y
-4.5%
52W High
$83.61
52W Low
$23.95
$23.95
52-Week Range
$83.61
How does IONS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IONS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
13.2
▲
3%
above
peers
(12.9)
vs Peers
vs Industry
Fair value
P/B ratio
9.4
▲
281%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IONS profitability vs Biotechnology peers
ROE
-44.3%
▲
34%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-26.5%
▲
91%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
98.7%
▲
26%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-8.7%
▲
81%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
IONS financial health vs Biotechnology peers
D/E ratio
198.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.8
▼
37%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.3
▼
72%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
IONS fundamentals radar
IONS
Peer median
Industry
IONS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IONS vs peers: key metrics
Latest News
RH CEO Warns Of 'Most Dire' Housing Market As Mortgage Applications Tumble …
Yahoo Finance · Apr 05
Globalstar Stock Pops More Than 15% After Report Claims Amazon In Talks …
Yahoo Finance · Apr 05
Stop Losing Money to Required Minimum Distributions and Use This Simple Fix
Nasdaq · Apr 04
Abu Dhabi Halts Operations At Main Gas Plant After "Falling Debris" From …
ZeroHedge · Apr 03
Allegations Of Pentagon "Casualty Cover-Up": The Intercept
ZeroHedge · Apr 03